Sarepta Therapeutics (SRPT) Stock: Soaring On Clinical Results

0

Sarepta Therapeutics Inc (NASDAQ: SRPT) is having an incredibly strong start to the trading session in the pre-market hours this morning, and for good reason. The company released results from a key clinical trial surrounding DMD. With the positive results in mind, excited investors sent the value of the stock soaring. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (8:53), SRPT is trading at $47.49 per share after a gain of $6.41 per share (15.60%) thus far today.





SRPT Releases Positive Clinical Data

As mentioned above, Sarepta Therapeutics is having an incredibly strong start to the trading session in the pre-market as a result of clinical data the company recently released with regard to a Phase 1/2 clinical study. The study surrounded golodirsen (SRP-4053) as a treatment for Duchenne Muscular
Dystrophy.

According to the release, all 25 boys involved in Part 2 of the clinical study experienced an increase in skipping exon 53 over baseline levels at week 48. In particular, mean dystrophy protein increased to 1.019% of normal compared to a mean baseline of 0.095% of normal. This data was determined via biopsies of the bicep muscle.




As a result of the positive data achieved, SRPT said that it will be submitting complete results for presentation at a future medical conference.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on SRPT. In particular, we’ll be keeping track of the ongoing work the company is doing in the Duchenne Muscular Dystrophy space, not only with golodirsen, but also with FDA-approved Exondys. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









LEAVE A REPLY

Please enter your comment!
Please enter your name here